Citra Anticoagulants Signs Exclusive Distribution Agreement with HAEMO-Pro for LOXXIT™ Catheter Lock Solution

Share Article

Citra Anticoagulants, Inc. reported that they signed a distribution agreement with HAEMO-Pro to distribute LOXXIT™ Catheter Lock Solution in Germany.

Citra Anticoagulants, Inc. a leading developer and worldwide distributor of citrate-based anticoagulants reported today that they signed a distribution agreement with HAEMO-Pro to distribute LOXXIT™ Catheter Lock Solution in Germany.

This agreement appoints HAEMO-Pro as the exclusive distributor of LOXXIT™ in Germany. Under the Agreement HAEMO-Pro will promote, market, and sell LOXXIT™. HAEMO-Pro is headquartered in Donaueschingen, Germany.

LOXXIT™ Catheter Lock Solution, 46.7% Trisodium Citrate Dihydrate, 5 mL, is a sterile solution that prevents the coagulation of blood, eliminates the growth of microorganisms in any type of intravenous catheter, and prevents biofilm formation because it eliminates the growth of bacteria, yeast, and fungi in the catheter lumen. LOXXIT™ is a preventive-action product and was designed to prevent problems from occurring rather than treating problems that have occurred.

For more information on LOXXIT™, visit To purchase LOXXIT™ in Germany, contact HAEMO-Pro at If you are a distributor in Europe, the Middle East, or Africa and are interested in distributing LOXXIT™, contact H.A.C. Pharma at For the rest of the world, contact Citra Anticoagulants at +1-781-848-2174 or

About Citra Anticoagulants
Headquartered in Braintree, Massachusetts, 10 minutes outside of Boston, Massachusetts, Citra Anticoagulants, Inc. markets and distributes a multitude of citrate-based anticoagulants to the worldwide medical arena. For more information about Citra and its products, visit

Team Citra embraces the mission to develop and market safe and effective citrate-based anticoagulants for the medical community, while providing outstanding customer service. Citra's products are used in many different applications: from the anticoagulant of choice in the preparation of platelet rich plasma, which is used as an aid in wound healing, to the anticoagulant of choice for the collection of granulocytes which are used to support patients undergoing cancer therapy, and to a superb catheter lock solution where the product functions as an anticoagulant and an antimicrobial agent.

About HAEMO-Pro
HAEMO-Pro GmbH & Co. KG was founded in 2002 and it is headquartered in Donaueschingen, Germany. The General Manager is Alois Käfer. HAEMO-Pro works in the field of Plasmatherapy and it is focused on medical devices for haemaphereses. For more information about HAEMO-Pro visit

# # #

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Ronald H. Lewis, Ph.D., President

Adrienne Summers
Visit website